Is INNATE PHARMA (OTCMKTS:IPHYF) a Buy? The Stock Reported Less Sellers

February 14, 2018 - By Ellis Scott

The stock of INNATE PHARMA (OTCMKTS:IPHYF) registered a decrease of 16.07% in short interest. IPHYF’s total short interest was 630,700 shares in February as published by FINRA. Its down 16.07% from 751,500 shares, reported previously. With 7,000 shares average volume, it will take short sellers 90 days to cover their IPHYF’s short positions.

The stock increased 6.02% or $0.355 during the last trading session, reaching $6.255. About shares traded. Innate Pharma S.A. (OTCMKTS:IPHYF) has 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Innate Pharma S.A., a clinical-stage biotechnology company, discovers, develops, and sells immunotherapies for cancer and inflammatory diseases in France. The company has market cap of $351.51 million. The firm offers Lirilumab , a human checkpoint inhibitor, which is in Phase I/II clinical trial for squamous cell carcinoma of the head and neck, as well as in Phase I and Phase II clinical trials in various combinations to treat solid and hematologic tumors; Monalizumab, an immune checkpoint inhibitor that is in Phase I/II clinical trial to treat various cancer indications, as well as in Phase I clinical trial for the treatment of solid tumors; and IPH4102, an anti-KIR3DL2 humanized antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas. It currently has negative earnings. It is also involved in developing IPH4301, a humanized anti-MICA/B therapeutic antibody to treat oncology; IPH52, an anti-CD39 antibody for immuno-oncology; IPH53, an anti-CD73 antibody for immuno-oncology; and IPH33, a monoclonal antibody program that targets Toll-like Receptor-3 receptor, which is an inducer of Type I IFN and pro-inflammatory cytokines; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils.

More notable recent Innate Pharma S.A. (OTCMKTS:IPHYF) news were published by: which released: “INNATE PHARMA : Results of Annual General Meeting and changes to Innate Pharma …” on June 26, 2017, also with their article: “INNATE PHARMA, First half of 2017: delivering key clinical data and …” published on September 18, 2017, published: “INNATE PHARMA : 2016 reference document made available (in french)” on April 03, 2017. More interesting news about Innate Pharma S.A. (OTCMKTS:IPHYF) were released by: and their article: “Innate Pharma and AstraZeneca announce global agreement for IPH2201 in immuno …” published on April 24, 2015 as well as‘s news article titled: “Bristol-Myers Squibb And Innate Pharma: Innovation Is Never A Single Event” with publication date: March 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.